Your browser doesn't support javascript.
loading
Structure-Enabled Discovery of a Stapled Peptide Inhibitor to Target the Oncogenic Transcriptional Repressor TLE1.
McGrath, Sally; Tortorici, Marcello; Drouin, Ludovic; Solanki, Savade; Vidler, Lewis; Westwood, Isaac; Gimeson, Peter; Van Montfort, Rob; Hoelder, Swen.
Affiliation
  • McGrath S; The Institute of Cancer Research, Division of Cancer Therapeutics Unit, Cancer Research UK Cancer Therapeutics Unit, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Tortorici M; The Institute of Cancer Research, Division of Cancer Therapeutics Unit, Cancer Research UK Cancer Therapeutics Unit, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Drouin L; The Institute of Cancer Research, Division of Cancer Therapeutics Unit, Cancer Research UK Cancer Therapeutics Unit, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Solanki S; The Institute of Cancer Research, Division of Cancer Therapeutics Unit, Cancer Research UK Cancer Therapeutics Unit, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Vidler L; The Institute of Cancer Research, Division of Cancer Therapeutics Unit, Cancer Research UK Cancer Therapeutics Unit, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Westwood I; The Institute of Cancer Research, Division of Cancer Therapeutics Unit, Cancer Research UK Cancer Therapeutics Unit, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Gimeson P; Malvern Instruments Nordic AB, Vallongatan 1, Uppsala, 752 28, Sweden.
  • Van Montfort R; Cancer Research (UK) Cancer Therapeutics Unit, Division of Cancer Therapeutics, Division of Structural Biology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
  • Hoelder S; The Institute of Cancer Research, Division of Cancer Therapeutics Unit, Cancer Research UK Cancer Therapeutics Unit, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
Chemistry ; 23(40): 9577-9584, 2017 Jul 18.
Article in En | MEDLINE | ID: mdl-28326635
ABSTRACT
TLE1 is an oncogenic transcriptional co-repressor that exerts its repressive effects through binding of transcription factors. Inhibition of this protein-protein interaction represents a putative cancer target, but no small-molecule inhibitors have been published for this challenging interface. Herein, the structure-enabled design and synthesis of a constrained peptide inhibitor of TLE1 is reported. The design features the introduction of a four-carbon-atom linker into the peptide epitope found in many TLE1 binding partners. A concise synthetic route to a proof-of-concept peptide, cycFWRPW, has been developed. Biophysical testing by isothermal titration calorimetry and thermal shift assays showed that, although the constrained peptide bound potently, it had an approximately five-fold higher Kd than that of the unconstrained peptide. The co-crystal structure suggested that the reduced affinity was likely to be due to a small shift of one side chain, relative to the otherwise well-conserved conformation of the acyclic peptide. This work describes a constrained peptide inhibitor that may serve as the basis for improved inhibitors.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oligopeptides / Peptides, Cyclic / Repressor Proteins Limits: Humans Language: En Journal: Chemistry Journal subject: QUIMICA Year: 2017 Document type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oligopeptides / Peptides, Cyclic / Repressor Proteins Limits: Humans Language: En Journal: Chemistry Journal subject: QUIMICA Year: 2017 Document type: Article Affiliation country: United kingdom